KIT and metastatic neoplasm: Extensive surgeries, including debulking procedures, after first-line imatinib therapy have been shown to extend OS in selected KIT/PDGFRA-mutant GIST patients with locally advanced (unresectable at diagnosis but not metastatic) and/or metastatic disease.23,24 Therefore, it is conceivable that, given the high response rate achieved with avapritinib in PDGFRA D842V-mutant GISTs, these types of surgical procedures may also be feasible in this subset of patients and obtain similar positive outcomes thus potentially expanding the survival in this population.